Literature DB >> 20576035

Narcoleptic orexin receptor knockout mice express enhanced cholinergic properties in laterodorsal tegmental neurons.

M Kalogiannis1, S L Grupke, P E Potter, J G Edwards, R M Chemelli, Y Y Kisanuki, M Yanagisawa, C S Leonard.   

Abstract

Pharmacological studies of narcoleptic canines indicate that exaggerated pontine cholinergic transmission promotes cataplexy. As disruption of orexin (hypocretin) signaling is a primary defect in narcolepsy with cataplexy, we investigated whether markers of cholinergic synaptic transmission might be altered in mice constitutively lacking orexin receptors (double receptor knockout; DKO). mRNA for Choline acetyltransferase (ChAT), vesicular acetylcholine transporter (VAChT) and the high-affinity choline transporter (CHT1) but not acetylcholinesterase (AChE) was significantly higher in samples from DKO than wild-type (WT) mice. This was region-specific; levels were elevated in samples from the laterodorsal tegmental nucleus (LDT) and the fifth motor nucleus (Mo5) but not in whole brainstem samples. Consistent with region-specific changes, we were unable to detect significant differences in Western blots for ChAT and CHT1 in isolates from brainstem, thalamus and cortex or in ChAT enzymatic activity in the pons. However, using ChAT immunocytochemistry, we found that while the number of cholinergic neurons in the LDT and Mo5 were not different, the intensity of somatic ChAT immunostaining was significantly greater in the LDT, but not Mo5, from DKO than from WT mice. We also found that ChAT activity was significantly reduced in cortical samples from DKO compared with WT mice. Collectively, these findings suggest that the orexins can regulate neurotransmitter expression and that the constitutive absence of orexin signaling results in an up-regulation of the machinery necessary for cholinergic neurotransmission in a mesopontine population of neurons that have been associated with both normal rapid eye movement sleep and cataplexy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20576035      PMCID: PMC2945818          DOI: 10.1111/j.1460-9568.2010.07259.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  58 in total

1.  Orexins/hypocretins excite basal forebrain cholinergic neurones.

Authors:  E Eggermann; M Serafin; L Bayer; D Machard; B Saint-Mleux; B E Jones; M Mühlethaler
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

2.  Application of real-time polymerase chain reaction for the quantitation of interleukin-1beta mRNA upregulation in brain ischemic tolerance.

Authors:  X Li; X Wang
Journal:  Brain Res Brain Res Protoc       Date:  2000-04

3.  Acetylcholine becomes the major excitatory neurotransmitter in the hypothalamus in vitro in the absence of glutamate excitation.

Authors:  A B Belousov; B F O'Hara; J V Denisova
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

4.  Differential expression of orexin receptors 1 and 2 in the rat brain.

Authors:  J N Marcus; C J Aschkenasi; C E Lee; R M Chemelli; C B Saper; M Yanagisawa; J K Elmquist
Journal:  J Comp Neurol       Date:  2001-06-18       Impact factor: 3.215

Review 5.  Carbachol models of REM sleep: recent developments and new directions.

Authors:  L Kubin
Journal:  Arch Ital Biol       Date:  2001-02       Impact factor: 1.000

6.  Direct and indirect excitation of laterodorsal tegmental neurons by Hypocretin/Orexin peptides: implications for wakefulness and narcolepsy.

Authors:  Sophie Burlet; Christopher J Tyler; Christopher S Leonard
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

Review 7.  Hypocretin/orexin, sleep and narcolepsy.

Authors:  M Hungs; E Mignot
Journal:  Bioessays       Date:  2001-05       Impact factor: 4.345

8.  Calcium-dependent regulation of cholinergic cell phenotype in the hypothalamus in vitro.

Authors:  Andrei B Belousov; Nicole D Hunt; Ryan P Raju; Janna V Denisova
Journal:  J Neurophysiol       Date:  2002-09       Impact factor: 2.714

9.  Chrna7 genotype is linked with alpha7 nicotinic receptor expression but not alpha7 RNA levels.

Authors:  Nathanial P Brooks; Sharon Mexal; Jerry A Stitzel
Journal:  Brain Res       Date:  2009-02-07       Impact factor: 3.252

10.  Reduced number of hypocretin neurons in human narcolepsy.

Authors:  T C Thannickal; R Y Moore; R Nienhuis; L Ramanathan; S Gulyani; M Aldrich; M Cornford; J M Siegel
Journal:  Neuron       Date:  2000-09       Impact factor: 17.173

View more
  15 in total

Review 1.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 2.  Control of sleep and wakefulness.

Authors:  Ritchie E Brown; Radhika Basheer; James T McKenna; Robert E Strecker; Robert W McCarley
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

Review 3.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 4.  Orexin/hypocretin receptor signalling cascades.

Authors:  J P Kukkonen; C S Leonard
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 5.  Optogenetic control of hypocretin (orexin) neurons and arousal circuits.

Authors:  Luis de Lecea
Journal:  Curr Top Behav Neurosci       Date:  2015

6.  Role of the hypocretin (orexin) receptor 2 (Hcrt-r2) in the regulation of hypocretin level and cataplexy.

Authors:  Ming-Fung Wu; Robert Nienhuis; Nigel Maidment; Hoa A Lam; Jerome M Siegel
Journal:  J Neurosci       Date:  2011-04-27       Impact factor: 6.167

7.  Distribution and intrinsic membrane properties of basal forebrain GABAergic and parvalbumin neurons in the mouse.

Authors:  James T McKenna; Chun Yang; Serena Franciosi; Stuart Winston; Kathleen K Abarr; Matthew S Rigby; Yuchio Yanagawa; Robert W McCarley; Ritchie E Brown
Journal:  J Comp Neurol       Date:  2013-04-15       Impact factor: 3.215

8.  A subset of cholinergic mushroom body neurons requires Go signaling to regulate sleep in Drosophila.

Authors:  Wei Yi; Yunpeng Zhang; Yinjun Tian; Jing Guo; Yan Li; Aike Guo
Journal:  Sleep       Date:  2013-12-01       Impact factor: 5.849

9.  Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Simon P Fisher; Tsui-Ming Chen; Deepti R Warrier; Thomas S Kilduff
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

10.  The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.

Authors:  Géraldine M Mang; Thomas Dürst; Hugo Bürki; Stefan Imobersteg; Dorothee Abramowski; Edi Schuepbach; Daniel Hoyer; Markus Fendt; Christine E Gee
Journal:  Sleep       Date:  2012-12-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.